These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 21199224)

  • 1. Fixed dose (555 MBq; 15 mCi) radioiodine for the treatment of hyperthyroidism: outcome and its predictors.
    Gupta SK; McGrath S; Rogers K; Attia J; Lewis G; Viswanathan S; Saul M; Allen L
    Intern Med J; 2010 Dec; 40(12):854-7. PubMed ID: 21199224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
    Bakker SC; Zanin DE; Zweers EJ
    Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA; Daykin J; Holder R; Sheppard MC
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
    Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
    Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
    Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results of two schedules of treatment for toxic multinodular goitre with radioiodine therapy.
    Khanna CM; Magdam M; Ravishankar L; Dham DN; Chugh P
    J Assoc Physicians India; 1995 Oct; 43(10):685-8. PubMed ID: 8773004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of hyperthyroidism with radioiodine: effects of administered dose on complications and thyroid function].
    Pineda P; Michelsen H; Rivera M; Lillo R; Massardo T; Araya V; Sierralta P; Oviedo S; Liberman C
    Rev Med Chil; 2000 May; 128(5):499-507. PubMed ID: 11008353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioiodine treatment of hyperthyroidism. Success rate and influence of thyrostatic medication.
    Ghadban WK; Zirie MA; Al-Khateeb DA; Jayyousi AA; Mobayedh HM; El-Aloosy AS
    Saudi Med J; 2003 Apr; 24(4):347-51. PubMed ID: 12754531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of four different protocols of I-131 therapy for treating single toxic thyroid nodule.
    Zakavi SR; Mousavi Z; Davachi B
    Nucl Med Commun; 2009 Feb; 30(2):169-75. PubMed ID: 19194214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioiodine treatment of hyperthyroidism in patients with low thyroid uptake.
    Ruchała M; Sowiński J; Dolata M; Junik R; Gembicki M; Skiba A
    Nucl Med Rev Cent East Eur; 2005; 8(1):28-32. PubMed ID: 15977144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
    Howarth D; Epstein M; Lan L; Tan P; Booker J
    Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome.
    Walter MA; Christ-Crain M; Eckard B; Schindler C; Nitzsche EU; Müller-Brand J; Müller B
    Eur J Clin Invest; 2004 May; 34(5):365-70. PubMed ID: 15147334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Graves' hyperthyroidism--prognostic factors for outcome.
    Alfadda A; Malabu UH; El-Desouki MI; Al-Rubeaan KA; Al-Ruhaily AD; Fouda MA; Al-Maatouq MA; Sulimani RA
    Saudi Med J; 2007 Feb; 28(2):225-30. PubMed ID: 17268701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs.
    Esfahani AF; Kakhki VR; Fallahi B; Eftekhari M; Beiki D; Saghari M; Takavar A
    Hell J Nucl Med; 2005; 8(3):158-61. PubMed ID: 16390021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Results of radioiodine treatment of patients with immunogenic and non-immunogenic hyperthyroidism using different focal doses].
    Moser E; Pickardt CR; Mann K; Engelhardt D; Kirsch CM; Knesewitsch P; Tatsch K; Kreisig T; Kurz C; Saller B
    Nuklearmedizin; 1988 Jun; 27(3):98-104. PubMed ID: 3405782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Radioiodine therapy of autonomously functioning thyroid nodules and Graves' disease].
    Guhlmann CA; Rendl J; Börner W
    Nuklearmedizin; 1995 Feb; 34(1):20-3. PubMed ID: 7724360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioiodine therapy in patients with amiodarone-induced thyrotoxicosis (AIT).
    Czarnywojtek A; Czepczynski R; Ruchala M; Wasko R; Zgorzalewicz-Stachowiak M; Szczepanek E; Zamyslowska H; Bartkowiak Z; Florek E; Sowinski J
    Neuro Endocrinol Lett; 2009; 30(2):209-14. PubMed ID: 19675515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External dose rates in radioiodine treatment of benign goitre: estimation versus direct measurement.
    Jørgensen HB; Høilund-Carlsen PF; Nielsen VE
    Scand J Clin Lab Invest; 2006; 66(6):509-16. PubMed ID: 17000558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioiodine treatment in autoimmune hyperthyroidism: analysis of outcomes in relation to dosage.
    Hernández-Jiménez S; Pachón-Burgos A; Aguilar-Salinas CA; Andrade V; Reynoso R; Ríos A; Reza-Albarrán AA; Mehta R; González-Treviño O; Gómez-Pérez FJ; Pérez-Enríquezi B; Rull JA
    Arch Med Res; 2007 Feb; 38(2):185-9. PubMed ID: 17227727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.